A patient undergoing groin lymph node dissection with spinal and general anaesthesia was receiving enalapril to control hypertension. Infusion of stable plasma protein solution (Commonwealth Serum Laboratories, Australia) was associated with significant hypotension and flushing. A brief review of stable plasma protein solution and angiotensin converting enzyme inhibitor pharmacology is presented to provide a possible mechanism for these events. This mechanism implies that angiotensin converting enzyme inhibitor therapy is a relative contraindication to rapid SPPS infusion.
She was placed in a sitting position, and a 26 gauge spinal needle inserted at L3-4, clear CSF seen, and bupivacaine 0.5% 3.5 ml heavy spinal solution injected. The patient then lay supine, and anaesthesia was induced with fentanyl 200 llg, atracurium 40 mg, propofol 120 mg and ventilated with halothane 0.5% in oxygen 6 lImin. She was intubated and transferred to the operating theatre table. Fresh gas flows were reduced to 2 l/min, halothane increased to 1 %, and IPPV with tidal volume 700 ml, 10 breaths/minute commenced, using a circle circuit. Initial postintubation systolic blood pressure was 100 mmHg, pulse rate 85 beats/minute. As the pulse rate fell to 60/minute, the systolic blood pressure fell to 90 mmHg. Metaraminol 0.5 mg was given and the systolic pressure rose transiently to 110 mmHg before slipping to 100 mmHg again. It was now fifteen minutes after her transfer to the operating table. Surgery had started five minutes previously, and there was no significant blood loss. The 1000 ml of lactated Ringer's having finished, stable plasma protein solution (SPPS) 500 ml was commencec;l at a fairly rapid rate, and as this was proceeding the pulse rate rose rapidly to 90-100 beats/minute. The systolic pressure Anaesthesia and Intensive Care, Vol. 18. No. 1. February. 1990 was now approximately 60 mmHg and the SPPS was continued as rapidly as possible. More metaraminol was drawn up and given to a total of 4.5 mg over the next ten minutes to maintain systolic blood pressure (SBP) at 90-95 mmHg. The halothane had been switched off, and fresh gas flow increased to 4 IImin. The pulse plethysmograph wave form continued to be of good amplitude in spite of the low blood pressure and a red flush was noted on all exposed skin. There were no wheals or oedema, nor was any wheeze heard. When the SPPS bottle finished, a further 1000 ml of lactated Ringer's was commenced. By the time 200 ml had been given the pulse rate had started to fall, and the systolic blood pressure was holding at 95 mmHg without further metaraminol. Over the next ten minutes the blood pressure rose to 160 mmHg and the pulse rate fell back to 60/minute. The red flush faded over the same period.
Halothane was reintroduced at up to 2%, and systolic blood pressure slowly fell over the next hour to 100-110 mmHg, while pulse rate remained stable. There was no abnormal bleeding, with final blood loss approximately 400 ml. The remainder of the procedure was uneventful, lasting two hours. No further SPPS was given.
DISCUSSION
The proposed mechanism of interaction is that substances with known vasodilator properties are present in SPPS and that their inactivation is delayed by inhibition of angiotensin converting enzyme. To support this hypothesis a brief review of SPPS and enalapril pharmacology is presented.
Stable plasma protein solution 5% (SPPS) is prepared by the Cohri cold ethanol fractionation process and pasteurisation from human plasma (volunteer donors), by Commonwealth Serum Laboratories, Melbourne, Australia.' It is iso-osmotic with human serum. It contains sodium octanoate 8 mmolll as a stabiliser during pasteurisation but no bacteriostatic agent.'
A range of adverse reactions to SPPS have been reported, including hypotension in response to rapid infusion (rate > 10 ml/min). This was thought, in 1980, 2 to be due to high levels of kin ins, prekallikrein activator (Hagemann factor fragments), and possibly Anaesthesia and Intensive Care. Vo!. 18. No. I. February. 1990 sodium acetate in the solution. The manufacturing process has been altered subsequently to ensure low levels of prekallikrein activator and sodium acetate in the final solution. The manufacturers state that the 'problem has been essentially overcome'. Nevertheless the product information sheet notes hypotension may still occur, especially with intra-arterial infusion during cardiopulmonary bypass or with rapid infusion.'
Enalapril is the oral form of the angiotensin converting enzyme (ACE) inhibitor, enalaprilic acid. It is well absorbed orally and the half-time for the conversion to enalaprilic acid by hepatic de-esterification is approximately two hours. Elimination halflife for enalaprilic acid is approximately five hours and elimination is primarily by renal excretion of unchanged enalaprilic acid. There is evidence of a dissociation of hypotensive effect from plasma converting enzyme activity, thought to be due to tight binding of the inhibitor to the enzyme in the vascular endothelium, with only slow release into plasma. 3 ACE, also known as kininase 11, has its main site of action in vascular beds, particularly in the lung. The discovery of agents able to inhibit its action has produced drugs which are extremely useful in the treatment of hypertension and heart failure. This has lead to their increasingly common use in patients presenting for surgery. What is less well-known is that this group of drugs were first recognised as inhibitors of bradykinin breakdown, rather than as inhibitors of ACE.
Bradykinin is the most potent vasodilator known in mammals and is broken down predominantly by kininase 11, the same enzyme responsible for the synthesis of angiotensin 11, the most potent pressor substance known. In the cardiovascular system, bradykinin causes dilation of most arterial beds, causing a sharp fall in systolic and diastolic pressures. In contrast, large arteries and most veins contract. Cardiac muscle is not directly affected, but the fall in total peripheral resistance and systemic blood pressure, combined with the increase in venous return due to contraction of the large veins, causes a reflex increase in heart rate and in cardiac output. Plasma half-life of kinins is normally of the order of fifteen seconds, with over 80% of kinins destroyed in a single passage through the pulmonary vascular tree. The predominant enzyme involved is kininase 11 (ACE), although other sloweracting enzymes also play a role. An example is kininase I, which usually abolishes kinin-like activity, although some of the breakdown products may be active in some damaged tissues. Kininase I is not known to be affected by ACE inhibitors. 4 The half-life of bradykinin in patients receiving ACE inhibitors is uncertain. Recent work suggests that although bradykinin may have little or no systemic effect in normal adults, ACE inhibition allows obvious systemic effects to appear. 5 In conclusion, it is postulated that despite changes in the manufacturing process, SPPS contains kinins or sufficient prekallikrein activator to cause significant kinin production. This patient had her major kinin breakdown pathway inhibited by enalapril which has been shown to potentiate the systemic effects of exogenous bradykinin in humans.
The severity of this patient's response to SPPS infusion may have been contributed to by the partial blockade of her sympathetic nervous system by major regional and general anaesthesia. Nevertheless it is clear that even low levels of kinins may have exaggerated effects in patients receiving ACE inhibitor therapy. If rapid expansion of intravascular volume is required in these patients then an artificial colloid may be a better choice than SPPS.
